Physician profile
Marivel Rapee
NPI 1235870726
$1,800.56
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,000 · 2023: $783 · 2024: $17.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.25 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $310.80 | 2022 | |
| Lilly USA, LLC | $203.36 | 2022-2023 | Mounjaro, Jardiance |
| Medtronic, INC. | $121.15 | 2022-2023 | Inpen Smart Insulin Delivery System |
| Astrazeneca Pharmaceuticals LP | $94.77 | 2022-2024 | Brilinta, Lokelma, Breztri |
| Novo Nordisk INC | $79.32 | 2022-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $62.97 | 2022-2023 | Xarelto |
| Phadia US INC. | $56.79 | 2023 | Immunocap |
| Pfizer INC. | $55.13 | 2023 | |
| Xeris Pharmaceuticals, INC. | $47.97 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $31.67 | 2022-2023 | Camzyos |
| Sunovion Pharmaceuticals INC. | $24.72 | 2022 | |
| Sumitomo Pharma America, INC. | $20.96 | 2023 | Gemtesa |
| Exact Sciences Corporation | $16.08 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.86 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $14.80 | 2023 | Inpefa |
| Mannkind Corporation | $14.08 | 2023 | Afrezza |
| Novartis Pharmaceuticals Corporation | $13.12 | 2023 | |
| Amgen INC. | $12.76 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marivel Rapee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.